Logo

CTVA

Corteva, Inc.

CTVA

Corteva, Inc. • NYSE
$67.47 ▲ 1.23% (+0.82)
Market Cap $45.59 B
52w High $77.41
52w Low $53.40
Dividend Yield 0.69%
P/E 27.32
Volume 1.93M
Outstanding Shares 675.73M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.618B ▼ $1.282B ▼ $-320M ▼ -12.223% ▼ $-0.47 ▼ $-24M ▼
Q2-2025 $6.456B ▲ $1.692B ▲ $1.314B ▲ 20.353% ▲ $1.93 ▲ $2.157B ▲
Q1-2025 $4.417B ▲ $1.248B ▲ $652M ▲ 14.761% ▲ $0.95 ▲ $1.116B ▲
Q4-2024 $3.978B ▲ $1.155B ▼ $-41M ▲ -1.031% ▲ $-0.06 ▲ $450M ▲
Q3-2024 $2.326B $1.226B $-524M -22.528% $-0.76 $-261M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.586B ▲ $42.198B ▲ $16.737B ▲ $25.219B ▼
Q2-2025 $2.141B ▲ $41.759B ▼ $15.608B ▼ $25.909B ▲
Q1-2025 $2.009B ▼ $42.123B ▲ $17.596B ▲ $24.285B ▲
Q4-2024 $3.169B ▲ $40.825B ▼ $16.795B ▼ $23.789B ▼
Q3-2024 $2.493B $41.908B $16.929B $24.737B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-395M ▼ $193M ▼ $-157M ▲ $367M ▲ $420M ▲ $36M ▼
Q2-2025 $1.382B ▲ $947M ▲ $-164M ▼ $-808M ▼ $22M ▲ $829M ▲
Q1-2025 $667M ▲ $-2.109B ▼ $-34M ▲ $995M ▲ $-1.127B ▼ $-2.203B ▼
Q4-2024 $-52M ▲ $4.173B ▲ $-123M ▲ $-3.336B ▼ $666M ▲ $3.992B ▲
Q3-2024 $-522M $130M $-161M $619M $615M $-24M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Biologicals
Biologicals
 $0 ▲$80.00M ▲$100.00M ▲$150.00M ▲
Crop Protection
Crop Protection
 $1.03Bn ▲$1.71Bn ▲$1.92Bn ▲$1.70Bn ▼
Fungicides
Fungicides
 $0 ▲$300.00M ▲$340.00M ▲$220.00M ▼
Herbicides
Herbicides
 $0 ▲$860.00M ▲$990.00M ▲$810.00M ▼
Insecticides
Insecticides
 $0 ▲$340.00M ▲$440.00M ▲$410.00M ▼
Other
Other
 $0 ▲$130.00M ▲$50.00M ▼$110.00M ▲
Seed
Seed
 $1.41Bn ▲$2.71Bn ▲$4.54Bn ▲$920.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Corteva’s revenue has been broadly stable in recent years, growing from the early years after its spin-off and then flattening out more recently. While sales are not surging, the company has steadily improved how much profit it keeps from each dollar of revenue, with gross and operating margins generally moving in the right direction. Earnings, however, have been bumpy. A very strong year a few years ago was followed by softer profit, and then a rebound more recently. That pattern suggests underlying businesses that are solid but influenced by swings in costs, pricing, currency, and one‑time items. Overall, the income statement shows a mature, scale player that is gradually getting more efficient but still experiences volatility in bottom‑line results.

Balance Sheet

Balance Sheet The balance sheet looks conservative and relatively stable. Total assets have hovered in a consistent range, reflecting a large, established operating base rather than rapid expansion or contraction. Shareholders’ equity has been steady as well, pointing to a business that is not stretching its finances aggressively. Debt has increased over time but remains moderate compared with the company’s equity and asset base, indicating a cautious use of leverage. Cash levels move around from year to year but stay healthy enough to provide flexibility. In plain terms, Corteva appears to be financed in a relatively balanced way, with no obvious signs of balance sheet stress.

Cash Flow

Cash Flow Corteva generates solid cash from its operations, but the pattern is uneven. Some years show very strong cash inflows, while at least one recent year was noticeably weaker, likely due to working capital swings or timing effects in a cyclical agricultural environment. After capital spending, the company has generally produced positive free cash flow, and investment in physical assets has stayed fairly steady rather than surging. That combination suggests Corteva can fund its ongoing investment needs internally while still having room to support shareholder returns or bolt‑on growth, though investors should recognize that cash generation can be lumpy from year to year.

Competitive Edge

Competitive Edge Corteva is one of the key global players in agricultural inputs, with strength across both seeds and crop protection. Its edge comes from a deep, long‑built library of seed genetics, strong proprietary traits, and a broad chemical and biological crop protection portfolio. Products like its Enlist weed control system and Qrome corn platform illustrate how it combines genetics and chemistry to solve specific on‑farm problems. The company also benefits from a distinctive go‑to‑market model: a mix of its flagship Pioneer brand, regional brands, licensing to other seed companies, and strong direct relationships with farmers. This high‑touch approach, together with an integrated offering that bundles seeds, crop protection, and digital tools, makes it harder for competitors to dislodge Corteva once it is embedded with a grower. At the same time, it competes against very large rivals and is exposed to the cyclical nature of farm incomes and changing regulations, so its moat is strong but not risk‑free.

Innovation and R&D

Innovation and R&D Corteva stands out for its heavy and consistent investment in research and development, spending a meaningful slice of its sales on innovation. This supports a broad pipeline across several fronts: advanced seed traits, new modes of action in herbicides and fungicides, biological solutions, and digital decision tools. On the seed side, its extensive germplasm and trait platforms, such as Enlist soybeans and Qrome corn, aim to deliver yield advantages and better pest and weed control. In crop protection, the company is rolling out new active ingredients that target resistance issues and environmental concerns. Corteva is also leaning into biological products and data‑driven farming tools, and it has ambitious projects on the horizon—shorter corn hybrids, hybrid wheat, gene‑edited traits, and integration of AI into agronomy. This sustained innovation push is a key pillar of its long‑term positioning but also brings execution, regulatory, and adoption risks that need to be watched.

Summary

Corteva looks like a scale agricultural inputs company with a solid, if somewhat cyclical, financial profile. Revenues are stable rather than fast‑growing, but profitability and margins have improved over time, even as earnings and cash flows bounce around from year to year. The balance sheet appears sound, with moderate leverage and adequate liquidity. Strategically, the company’s strength lies in its combination of deep genetics, differentiated crop protection chemistry, rising biologicals, and digital tools, all delivered through a high‑touch, multi‑channel sales model. Its substantial R&D commitment and strong pipeline underpin a credible innovation story that could support long‑term growth and pricing power. Key things to monitor include: how well new products are adopted, how effectively Corteva manages agricultural cycles and cost inflation, and whether its substantial innovation spending continues to translate into durable competitive advantages and consistent cash generation.

NEWS

November 11, 2025 · 8:30 AM UTC

IBI Ag Completes $10 Million Series A Round Led by Corteva

Read more

November 5, 2025 · 10:15 AM UTC

Corteva Announces Groundbreaking, Nature-Inspired Solutions to Control Insects, Help Farmers Effectively Protect Yield

Read more

November 4, 2025 · 4:30 PM UTC

Corteva Raises Full-Year Guidance on Strong Third Quarter and Year-To-Date 2025 Results

Read more

October 31, 2025 · 8:00 AM UTC

Corteva Declares Quarterly Dividend

Read more

October 14, 2025 · 7:15 AM UTC

Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection Co-Led by Acre Venture Partners and Corteva

Read more